التفاصيل البيبلوغرافية
| العنوان: |
Angiotensin converting enzyme inhibitors and vasodilators |
| المؤلفون: |
Squire, Iain, Clark, Andrew L. |
| المساهمون: |
Clark, Andrew L., Gardner, Roy S., McDonagh, Theresa A. |
| المصدر: |
Oxford Textbook of Heart Failure ; page 607-616 |
| بيانات النشر: |
Oxford University Press |
| سنة النشر: |
2022 |
| الوصف: |
This chapter details how, during the 1980s and 1990s, evidence mounted for the central role to the pathophysiology of chronic heart failure of activation of the renin–angiotensin–aldosterone system (RAAS) and adrenergic nervous system. Over those years and into the early part of the twenty-first century, large randomized, controlled trials provided physicians with enormous amounts of evidence for the benefits to patients with heart failure of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor antagonists, mineralocorticoid receptor antagonists, and β-receptor blockers, in addition to diuretics and digoxin. The chapter then reviews the development and pharmacology of ACE inhibitors and their physiological actions. It also discusses the side-effect profile of ACE inhibitors and the place of vasodilators which do not block the RAAS as potential alternatives to ACE inhibition. Moreover, the chapter looks at the huge clinical impact of ACE inhibitors in the treatment of heart failure. |
| نوع الوثيقة: |
book part |
| اللغة: |
unknown |
| DOI: |
10.1093/med/9780198766223.003.0048 |
| الإتاحة: |
https://doi.org/10.1093/med/9780198766223.003.0048Test |
| رقم الانضمام: |
edsbas.B6643969 |
| قاعدة البيانات: |
BASE |
